Aethlon Medical (NASDAQ:AEMD) Earns Neutral Rating from HC Wainwright

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. HC Wainwright also issued estimates for Aethlon Medical’s Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.14) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.49) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at ($0.33) EPS.

Separately, Wall Street Zen began coverage on shares of Aethlon Medical in a report on Thursday, May 15th. They set a “sell” rating for the company. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.00.

Aethlon Medical Stock Performance

Shares of AEMD stock traded down $0.0250 during trading hours on Thursday, hitting $1.1050. The company had a trading volume of 39,104 shares, compared to its average volume of 143,461. The firm has a market capitalization of $2.87 million, a price-to-earnings ratio of -0.09 and a beta of 1.72. Aethlon Medical has a 12 month low of $1.0846 and a 12 month high of $8.44. The firm’s fifty day moving average is $1.36 and its 200 day moving average is $2.75.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.17). On average, sell-side analysts expect that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Boothbay Fund Management LLC bought a new position in Aethlon Medical in the fourth quarter valued at $186,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical during the 4th quarter valued at about $31,000. Armistice Capital LLC bought a new stake in Aethlon Medical in the 1st quarter worth approximately $511,000. Finally, Renaissance Technologies LLC purchased a new stake in Aethlon Medical in the fourth quarter worth approximately $25,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.